UE 2343

Drug Profile

UE 2343

Alternative Names: UE2343; Xanamem

Latest Information Update: 17 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Edinburgh
  • Developer Actinogen Medical; University of Edinburgh
  • Class Antidementias; Small molecules
  • Mechanism of Action 11-beta hydroxysteroid dehydrogenase type 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease

Most Recent Events

  • 16 Aug 2017 Phase-II clinical trials in Alzheimer's disease in United Kingdom (PO)
  • 26 Jul 2017 Actinogen Medical plans to complete enrolment in the phase II XanADU trial for dementia associated-Alzheimer's disease in USA, Australia and United Kingdom by the fourth quarter of 2018
  • 26 Apr 2017 Actinogen Medical and the University of Edinburgh plan a phase II trial for Cognition disorders (Diabetic Cognitive Impariment)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top